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Prostate‑specific antigen (PSA) and the 
controversy in PSA screening
In 2015, prostate cancer (PC) was the most commonly 
diagnosed male malignancy, not only in western countries 
[1], but also in Japan [2]. PSA is the most commonly used 
biomarker for the early detection of PC. After the intro-
duction of PSA testing, the rate of PC diagnosis increased 
and PC-associated mortality decreased. Elevated PSA lev-
els are associated with an increased risk of PC, a higher 
pathological grade, and an increased risk of metastatic 
disease [3]. However, the use of PSA as a biomarker has 
a number of limitations. First, PSA is not a PC-specific 
biomarker. In addition, PSA levels are influenced by sev-
eral factors, including age, acute prostatitis, ejaculation, 
catheterization, and certain medications. Furthermore, 
there is no precise value indicative of a lack of PC risk, 
and PSA levels cannot distinguish between indolent and 
aggressive disease, particularly at PSA levels below 20 ng/
mL. In one study, the conventional cutoff value of 4 ng/
mL PSA predicted PC in 10- or 12-core needle biopsies 
in only 30–40 % of patients [4]. In addition, ~15 % of 
men with serum PSA levels below 4 ng/mL are reported 
to be at risk for PC [5]. A precise PSA cut-off value that 
can facilitate the early detection of PC with high sensitiv-
ity and specificity in healthy men has not yet been defined. 
In addition, the ideal age at which to initiate or discon-
tinue PSA testing, and the appropriate frequency of testing 
remain unclear. Two recent randomized trials evaluating 
the effect of PSA-based screening on mortality reduction 
reported conflicting results [6, 7]. Together, these findings 
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prognosis has improved the clinical management of PC 
patients. However, the PSA assay has been faced with criti-
cism due to its potential association with over-diagnosis 
and subsequent overtreatment of patients with indolent 
disease. The United States Preventive Services Task Force 
incited much debate over PSA-based screening in 2012 by 
recommending against this approach. However, the PSA 
assay remains the first-line tool for the early detection of 
PC. This debate highlights the unmet need for non-inva-
sive PC biomarkers with greater sensitivity and specificity 
that are capable of distinguishing aggressive disease from 
indolent disease, predicting treatment response, and guid-
ing treatment decisions. Recent investigations into putative 
PC biomarkers have focused on PSA isoform assays (pros-
tate health index, 4-kallikurein panel), PC-associated genes 
in the urine (PCA3 and TMPRSS2-ERG), glycan-asso-
ciated biomarkers (S2, 3PSA, GCNT1, and tri- and tetra-
antennary serum N-glycans), and circulating tumor cells. 
Although substantial efforts to identify novel PC biomark-
ers that might replace PSA have been put forth, the major-
ity of the putative PC biomarkers reported in the last few 
years are still under investigation or validation. This review 
provides an overview of the current state of PC biomarker 
research and focuses on a few promising PC biomarkers in 
development.
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prompted the United States Preventive Services Task Force 
to recommend against the use of PSA-based screening in 
2012 [8]. Nevertheless, as there are no other reliable PC 
biomarkers to replace PSA, PSA screening remains the 
first-line assay for PC detection. As this approach is the 
subject of much debate and controversy, there is an unmet 
need for the identification of novel biomarkers with high 
sensitivity and specificity for detecting PC and predicting 
aggressive disease. Recently identified putative PC bio-
markers are described in Table 1.
PSA isoforms
Serum PSA predominantly exists in a complex with α-1-
antichymotrypsin. Levels of unbound PSA, referred to as 
free PSA (fPSA), are calculated using the following for-
mula fPSA = total PSA − α-1-antichymotrypsin-bound 
PSA. %fPSA is associated with a greater specificity for 
detecting PC in men with a total PSA between 4 and 10 ng/
mL [9, 10]. Three isoforms of fPSA are found in the serum: 
(1) proPSA, (2) intact PSA, and (3) benign PSA. There are 
also several truncated isoforms of proPSA, including [−2]
proPSA, [−5]proPSA, and [−7]proPSA. [−2]proPSA is 
the predominant proPSA isoform in tumor extracts [11], 
suggesting that it has the potential to play a role in the early 
detection of PC and the prediction of aggressive disease 
[12] (Fig. 1).
Prostate health index (PHI)
The prostate health index (PHI) is an assessment of the 
three PSA isoforms. PHI is calculated using the follow-
ing formula: ([−2]proPSA/fPSA) × PSA1/2. The test was 
developed by Beckman Coulter in partnership with the 
NCI Early Detection Research Network. The aim of PHI 
is to distinguish between malignant and benign prostate 
conditions in men 50 years or older with normal digital 
rectal exam (DRE) results and PSA levels of 4–10 ng/
mL, and to ultimately reduce the number of unneces-
sary biopsies performed. Several studies have suggested 
that PHI significantly improves prostate cancer detection 
in high-risk cases [11, 13] and that is associated with PC 
aggressiveness [12]. PHI and [−2]proPSA were approved 
by the US Food and Drug Administration (FDA) in 2012. 
PHI has been gaining acceptance worldwide and has been 
approved for clinical use in more than 50 countries. How-
ever, it is not yet recommended as a first-line screening 
method for all patients due to a lack of sufficient data. 
Further prospective analysis of this approach is needed to 
support its use as a first-line screening tool for PC in all 
patients.
4K score
The 4K score is an assessment of kallikrein-related pep-
tide 2 (hK2) and the three PSA isoforms included in the 
Table 1  Recently identified putative prostate cancer biomarkers
Biomarker Biomaterial Applications Marker description
PHI Serum Diagnostic Total PSA, [−2]proPSA, fPSA
PCA3 Urine Diagnostic PSA and PCA3 mRNA
4K score Plasma Diagnostic Total PSA, fPSA, intact PSA
S2, 3PSA Serum Diagnostic Aberrant glycosylation in serum PSA
TMPRSS2-ERG Urine, blood tissue Diagnostic Fusion gene of ERG and transmembrane protease, serine 2
Mi-Prostate score Urine Diagnostic PSA, PCA3 and TMPRSS2-ERG mRNAs
miRNA Serum, plasma, 
urine
Diagnostic/aggressiveness Altered miRNA expression profiles (miR-141, -375, -21, -107, 221, 
etc.)
Oncotype DX Tissue Aggressiveness 12 Cancer-related genes: androgen pathway (AZGP1, KLK2, SRD5A2, 
RAM13C), proliferation (TPX2), cellular organization (FLNC, GSN, 
TPM2, GSTM2) and stromal response (BGN, COL1A1 and SFRP4).
ProMark Tissue Aggressiveness 8 Proteins (DERL1, CUL2, SMAD4, PDSS2, HSPA9, FUS, phospho-
rylated S6, YBOX1)
Prolaris Tissue Aggressiveness 31 Cell cycle progression genes and 15 housekeeping genes in combina-
tion with PSA and Gleason score
Decipher GC Tissue Aggressiveness (metas-
tasis)
22 RNAs form tissue after radical prostatectomy
GCNT1 Urine, tissue Aggressiveness Overexpression of the enzyme that forms core 2-branched O-glycans
N-glycans Serum Aggressiveness Aberrant glycosylation in serum N-glycans
AR-V7 Blood Aggressiveness AR-V7 expression in CTCs
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PHI (total PSA, fPSA, and intact PSA). The 4K score 
also incorporates clinical information, including age and 
history of prior negative biopsy, to provide an estimate 
of the probability of biopsy-confirmed PC. Retrospective 
studies reported that the 4K score was more accurate in 
predicting clinically diagnosed PC [14] and aggressive 
disease [15] compared with PSA and age. A recent meta-
analysis reported that the 4K score is associated with a 
improvement of 8–10 % in predicting biopsy-confirmed 
PC, indicating that the use of the 4K score could poten-
tially eliminate the number of prostate biopsies currently 
conducted by an estimated 48–56 % [16]. Although the 
accuracy of the 4K score highlights the drawbacks of 
PSA screening, it is not yet FDA-approved or included in 
current guideline recommendations. Furthermore, as no 
comparative study has been reported, it is unclear if the 
predictive accuracy of the PHI and the 4K score differs. 
Therefore, additional prospective studies are needed to 
evaluate their use as screening tools for the early detec-
tion of PC.
Genomic biomarkers in urine
Progensa PCA3 assay
Prostate cancer gene 3 (PCA3) is prostate-specific non-
coding mRNA that is strongly expressed in patients with 
PC. The PCA3 assay measures the concentration of PCA3 
and PSA RNA molecules. The PCA3 score is calculated 
as the ratio of PCA3 RNA molecules to PSA RNA mole-
cules (PCA3 score) in post-DRE urine specimens. A PCA3 
score less than 25 indicates a low risk of PC [17]. The test 
was approved by the FDA in 2012. It is used to help deter-
mine if a repeat biopsy is necessary for men with a previ-
ous negative biopsy. A meta-analysis of 11 clinical studies 
reported that the sensitivity of the PCA3 assay ranged from 
53 to 69 % and the specificity ranged from 71 to 83 % [18]. 
A more recent meta-analysis of 11 studies reported that 
a sensitivity and specificity of 72 and 53 %, respectively, 
was associated with a PCA3 score cut-off of 20 [19]. These 
findings indicate that the PCA3 test might be more accurate 
Fig. 1  PSA synthesis and PSA isoforms. PSA synthesis begins with 
the cleavage of the proenzyme PSA (proPSA) leader sequence from 
preproPSA. There are several truncated isoforms of proPSA, includ-
ing [−7]proPSA, [−5]proPSA, and [−2]proPSA. [−2]proPSA is the 
predominant proPSA isoform in tumor extracts, indicating that it has 
the potential to play a role in the early detection of PC and the predic-
tion of aggressive disease. The cleavage of the propeptide in proPSA 
by human kallikrein 2 (hk2) generates the mature PSA molecule. 
Benign PSA (BPSA), intact PSA, and [−2]proPSA exist as free PSA 
molecules in the serum. cPSA complexed PSA
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compared with other methods used for the early detection 
of PC. The Progensa PCA3 assay has been included in the 
EAU guidelines for repeat biopsy decision-making.
The TMPRSS2‑ERG fusion gene
Gene rearrangements have been observed in multiple can-
cers, and they are especially prevalent in leukemia (e.g., 
the Philadelphia chromosome). The TMPRSS2-ERG 
fusion gene, comprising the androgen-responsive genes 
transmembrane protease, serine 2 (TMPRSS2), and estro-
gen-regulated gene (ERG), was observed in ~40–80 % of 
prostate cancers in 2005 [20]. Both genes are located on 
chromosome 21. The TMPRSS2-ERG score is calculated 
using the following formula: (TMPRSS2-ERG mRNA/PSA 
RNA copies) × 100,000. Levels of urine TMPRSS2-ERG 
appear to be associated with clinically significant PC [21]; 
however, the prognostic significance of TMPRSS2-ERG is 
unclear. A recent meta-analysis suggested that TMPRSS2-
ERG overexpression is associated with tumor stage, but that 
it is not associated with disease recurrence or mortality in 
men treated with radical prostatectomy (RP) [22].
Mi‑Prostate score (MiPS)
TMPRSS2-ERG is a PC-specific fusion gene. However, 
most prostate tumors have multiple foci and the expression 
of TMPRSS2-ERG is thought to be heterogeneous. The 
MiPS overcomes this limitation by assessing multiple PC-
associated parameters. MiPS combines the prognostic signif-
icance of urine TMPRSS2-ERG and PCA3 with serum PSA 
to generate a PC risk assessment score. In a recent validation 
study with 1225 patients, MiPS was superior to serum PSA 
alone in predicting biopsy-confirmed PC and high-grade PC 
[23]. However, this test is not yet FDA-approved.
Genomic and protein biomarkers in tissue
Oncotype DX test
The Oncotype DX test is a multi-gene expression assay 
developed for formalin-fixed paraffin-embedded diagnostic 
prostate needle biopsies. The assay measures the expres-
sion of 12 cancer-related genes representing 4 distinct 
biological functions: androgen signaling (AZGP1, KLK2, 
SRD5A2, and RAM13C), proliferation (TPX2), cytoskel-
etal organization (FLNC, GSN, TPM2, GSTM2), and the 
stromal response (BGN, COL1A1, and SFRP4). Five ref-
erence genes have been included to normalize the data 
and control for variability. The gene expression levels are 
algorithmically combined to calculate a genomic prostate 
score (GPS). The Oncotype DX test has been validated as 
a predictor of prostate cancer aggressiveness, and it facili-
tates prostate cancer risk stratification to help guide treat-
ment decision-making [24]. It is included as a potential 
option in the National Comprehensive Cancer Network 
(NCCN) guidelines of 2015, with the disclaimer that fur-
ther studies of the assay are still needed [25].
Prolaris test
The Prolaris test is a multi-gene expression assay (46 
genes) developed for formalin-fixed paraffin-embedded tis-
sue derived from prostate needle biopsies. It is used in con-
junction with the Gleason score and serum PSA to predict 
prostate cancer aggressiveness. The Prolaris test assesses 
disease progression by quantitatively analyzing the expres-
sion of 31 genes associated with cell cycle progression and 
15 housekeeping genes. Low expression levels of these 
genes are associated with a low risk of disease progres-
sion, whereas high expression levels are indicative of a 
higher risk of disease progression [26]. The Prolaris test is 
included in the NCCN 2015 guidelines.
Decipher genomic classifier (Decipher GC)
Decipher is a genomic classifier (GC) test that uses a whole-
transcriptome microarray assay to analyze the expression of 
22 genes in formalin-fixed paraffin-embedded prostate can-
cer specimens obtained from RP. Decipher GC can predict 
the risk of metastasis following RP. In a clinical validation 
study, Decipher was a more accurate predictor of metasta-
sis post-RP compared with individual clinical variables, with 
an area under the curve (AUC) of 0.79 for predicting 5-year 
metastasis risk [27]. A genomic risk stratification assay using 
the primary tumor can identify patients at a high risk for 
metastasis and potentially lethal prostate cancer, thereby pro-
viding information that can improve treatment decision-mak-
ing post-RP. The Decipher score is included in the NCCN 
2015 guidelines as a post-RP prognostic marker. The specific 
genes evaluated and the formula used to calculate the Deci-
pher GC score have not been published.
ProMark
ProMark is a prognostic assay that analyzes the expres-
sion of 8 protein biomarkers in formalin-fixed paraffin-
embedded tissue obtained from prostate needle biopsies. It 
is used to predict prostate cancer aggressiveness, particularly 
in patients with a Gleason score 3 + 3 or 3 + 4. ProMark 
quantitatively analyzes the levels of 8 proteins (DERL1, 
CUL2, SMAD4, PDSS2, HSPA9, FUS, phosphorylated S6, 
and YBOX1) in biopsy tissue sections using an automated 
immunofluorescence method. The protein levels are used to 
calculate a risk score that has been clinically validated as an 
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independent predictor of prostate cancer aggressiveness [28]. 
The ProMark score can help distinguish patients that should 
be actively monitored from those that require therapeutic 
intervention.
Cancer‑associated glycan biomarkers
Cancer-associated glycan aberrations are frequently 
observed in tumors. The majority of tumor markers, includ-
ing PSA, are glycoproteins that have glycosylation sites in 
their amino acid sequence. Importantly, each glycan exhib-
its specific cancer-associated carbohydrate aberrations com-
pared with its normal counterpart, and these aberrations can 
be detected using specific monoclonal antibodies or lectin.
Aberrant serum PSA glycosylation (S2,3PSA)
PSA is a glycoprotein with a single N-glycosylation site at 
an asparagine (N) residue 45 amino acids from the N-termi-
nus. In patients with PC, the terminal N-glycan structure of 
PSA is rich in sialic acid α2,3-linked galactose, whereas the 
terminal N-glycan structures of PSA from healthy patients 
are predominantly α2,6-linked [29] (Fig. 2). Based on this 
finding, Yoneyama et al. successfully developed a novel 
assay using a magnetic microbead-based immunoassay 
to detect α2,3-linked sialylation on free PSA (S2, 3PSA) 
[30]. The diagnostic accuracy of S2, 3PSA was associated 
with an AUC of 0.84, and the sensitivity and specificity of 
the assay was 95.0 and 72.0 %, respectively, a significant 
increase compared with PSA or %fPSA. Although the 
study was small and preliminary, the results suggest that 
assays measuring cancer-associated glycan alterations in 
serum S2, 3PSA might improve the accuracy of early PC 
detection and reduce unnecessary prostate biopsies.
Highly branched (tri‑ or tetra‑antennary) serum 
N‑glycans
Although cancer-associated glycan alterations represent 
potential cancer biomarkers, glycan analysis has not been 
incorporated into clinical use because the protocols for pre-
paring glycan derivatives vary depending on the analytical 
method and conducting these protocols requires specialized 
expertise. Therefore, a practical procedure for analyzing 
a large number of glycan samples in biological materials 
such as serum is not currently available.
Recently, an approach that combines high-throughput, 
quantitative N-glycomics with mass spectrometry analysis 
was developed. The technique is based on a chemoselective 
glycan enrichment technology that enables the purification 
of oligosaccharides from 10 μL of crude glycoproteins. 
Preliminary results indicate that serum N-glycan analysis 
is a promising approach to screening diagnostic and prog-
nostic markers associated with multiple types of cancer 
[31, 32]. Ishibashi et al. evaluated the potential predictive 
value of serum N-glycomics in patients with castration-
resistant PC (CRPC) [33]. They used serum N-glycomics 
with the glycoblotting method to analyze 80 healthy volun-
teers, 286 patients with benign prostatic hyperplasia, 258 
Fig. 2  Aberrant glycosylation 
of PSA N-glycans (S2, 3PSA) 
in PC. In healthy patients, the 
terminal sialic acid of PSA is 
predominantly α2,6-linked to 
galactose residues. In patients 
with PC, the terminal sialic acid 
is predominantly α2,3-linked to 
galactose residues
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patients with early-stage PC, 46 patients with PC that had 
been treated with androgen deprivation therapy (ADT), 
and 68 patients with CRPC. They found that tri- and tetra-
antennary N-glycans were significantly enriched in patients 
with CRPC compared with the other groups. The longitudi-
nal follow-up of highly branched N-glycan levels predicted 
CRPC despite castrate levels of testosterone. These results 
suggest that the overexpression of specific N-glycans might 
be associated with CRPC and that it might represent a pre-
dictive CRPC biomarker.
Core2 β‑1,6‑N‑acetylglucosaminyltransferase (GCNT1)
Core2 β-1,6-N-acetylglucosaminyltransferase-1 (GCNT1) 
is an enzyme that plays a key role in the formation of core 
2-branched O-glycans, and GCNT1 expression is associ-
ated with the progression of several types of cancer [34–
37]. GCNT1 expression is strongly associated with disease 
aggressiveness in patients with PC [38–40]. Kojima et al. 
recently evaluated the utility of GCNT1 for the detection 
of aggressive PC using immunohistochemistry and immu-
noblotting assays in post-DRE urine [41]. They reported 
that over 90 % of GCNT1-positive PC patients with high 
concentrations of PSA presented with extracapsular 
extensions, further confirming that GCNT1 expression is 
strongly associated with aggressive PC. Further research is 
needed to develop an efficient assay that can detect GCNT1 
in post-DRE urine and facilitate the use of GCNT1 as a 
marker of PC aggressiveness in the clinical setting.
Circulating tumor cells (CTCs)
Circulating tumor cells (CTCs) are tumor cells that have 
shed into the peripheral circulation from solid malignancies. 
CTCs have generally been considered surrogates for meta-
static cells, and CTCs levels in patients undergoing treatment 
have proven to be a response marker with a strong independ-
ent prognostic value [42]. In addition, CTCs have been char-
acterized as a ‘‘liquid biopsy” that can facilitate the real-time 
monitoring of therapeutic efficacy, and the identification of 
therapeutic targets and resistance mechanisms [43].
Recently, the presence of the AR splice variant 7 (AR-
V7) in CTCs was shown to be strongly associated with 
resistance to anti-AR therapy [44]. The presence of AR-V7 
in CTCs was associated with poor overall survival, with 
a hazard ratio (HR) of 6.9 [95 % confidence interval (CI) 
1.7–28.1, P = 0.002] in patients receiving enzalutamide 
cohort and an HR of 12.7 (95 % CI 1.3–125.3, P = 0.006) 
in patients receiving abiraterone cohort. The same group 
also reported that the presence of AR-V7 did not signifi-
cantly influence the effect of taxane treatment [45]. More 
recently, Scher et al. reported similar results from a pro-
spective study of 191 blood samples from patients with 
metastatic CRPC. Although the proportion of patients with 
AR-V7-positive CTCs in this study was relatively low 
(34/191 samples, 18 %), AR-V7 positive patients were 
resistant to AR inhibition therapy, were on therapy for less 
time, and experienced a reduction in radiographic pro-
gression-free survival and overall survival compared with 
Fig. 3  Overview of potential 
prostate cancer biomarkers. 
Novel biomarkers were clas-
sified according to screening 
to prognostic phase based on 
types of biomaterials. Asterisk 
US FDA approved, N/A not 
available
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patients with AR-V7-negative CTCs [46]. However, there 
are substantial limitations to the clinical application of 
AR-V7 monitoring as only half of patients have detectable 
CTCs, CTSs cannot be stored, and the procedure is costly 
and can only be conducted in specialized labs. Although 
AR-V7 appears to be a promising prognostic factor, addi-
tional studies and technological innovations are needed to 
facilitate its widespread clinical use.
Conclusion and perspectives
Although serum PSA has been used as a prostate can-
cer biomarker for several decades, studies demonstrating 
its limitations have incited much controversy and debate. 
The ideal PC biomarker would be capable of distinguish-
ing PC from benign prostate conditions and differentiating 
between aggressive and indolent tumors. Recent techno-
logical innovations have led to substantial improvements 
in biomarker screening assays. An overview of the emerg-
ing prostate cancer biomarkers described in this review are 
summarized in Fig. 3. Specifically, two new tests designed 
to help determine the need for prostate biopsy have recently 
been approved by the US FDA. Currently, the incorpora-
tion of new biomarkers appears to be a promising approach 
for improving the sensitivity and specificity of PSA assays. 
However, comparative studies evaluating these various bio-
marker assays are still needed, as are studies with larger 
sample sizes and improvements in cost effectiveness. 
Large-scale, prospective trials can help evaluate the util-
ity of these new approaches in multiple clinical contexts. 
The use of novel biomarkers that can serve as alternatives 
to PSA appears to be a promising approach to improving 
risk assessment strategies and has the potential to improve 
outcomes in patients with PC.
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